Three big-ticket deals contributed 69 per cent of total deal value in November 2020

In November 2020, the healthcare industry reported 58 deals worth $13.5 billion as compared to the last 12-month average (November 2019 to October 2020) of 81 deals worth $14.5 billion.

CBPO Group to acquire China Biologic Products Holdings, an integrated plasma-based biopharma company for an equity value of approximately $4.7 billion;  Merck & Co to acquire all outstanding shares of VelosBio, a clinical-stage biopharmaceutical company developing novel, ROR1-directed therapeutics for $2.7 billion; Novo Nordisk A/S to acquire Emisphere Technologies (Emisphere), a drug delivery company with proprietary technologies, such as the Eligen SNAC technology, which enable oral formulations of therapeutics, for $1.8 billion are the three major deals that contributed 69 per cent of the total deal value during November 2020.

Venture capital investments value increased in November 2020

The healthcare industry reported 91 venture capital (VC) deals worth $3.3 billion in November 2020, compared to the last 12-month average (November 2019 to October 2020) of 119 deals worth $2.7 billion.

RecBio, a biotechnology company raising $227 million in series B round of financing to build a production base and conduct clinical tests of its 9-valent HPV vaccine and recombinant COVID vaccine; D3 Bio, a biotechnology company focused on developing and commercialising precision medicines, raising $200 million in series A round of financing to support the development of its portfolio in oncology and immunology; and CARsgen Therapeutics Holdings, a biotechnology company raising $186 million in series C round of financing to accelerate global clinical trials of its cell therapy product candidate are the major VC deals reported in November 2020.